Media OutReach
Bora Delivers Highest Operating Cash Flow Margin Since 2020, Enabling 2026 Bolt-On Investments from a Larger, Stronger Platform
Board Proposed NT$10 Cash Dividend Per Share
HONG KONG SAR – Media OutReach Newswire – 11 March 2026 – Bora Pharmaceuticals (“Bora”; TWSE: 6472; OTCQX: BORAY) today announced its financial results and operational highlights for full year 2025 and provides 2026 outlook.
FY25 Business and Financial Highlights
- Company reported full year revenues, with discontinued operations reported separately, of NT$19,014 million, up 9.11% from the prior year and basic EPS of NT$23.90, or NT$2.63 for the fourth quarter. Full year EPS represents a 24.22% year-over-year decline, mostly due to a net loss per share of NT$11.24 from discontinued operations.
- In the fourth quarter, following the completion of tech transfer of production transitions out of the Plymouth area in Minnesota, the COGS of those originally Plymouth-made inventories have been reconsolidated to COGS line. Hence on a like-for-like basis when compared with other quarters in 2025, fourth quarter gross margin would have been approximately 38-39%. The reported high single-digit percentage sequential decline in gross margin, which also led to softened operational leverage, was primarily attributable to a temporary slowdown in DLS orders from following the entry of a new competitor in Nov. with limited launch visibility during the quarter. Higher effective tax rates during the quarter were a direct result of less sell-through downstream from related party transactions of the internally manufactured generic products. In addition, heightened generics competition of Topiramate ER, a leading generics product of Upsher-Smith, was also a negative gross margin mover.
- Management believes the 4Q25 OPEX profile more accurately reflects the expanded operating platform and our strategic repositioning into new focus areas. Sales and marketing expenses increased seasonally in line with market share cadence and channel expansion initiatives, while R&D spending sat on the disciplined side. Gross margin expansion serves as the key lever for operating leverage as scale improves fixed-cost absorption.
- Pharma sales revenue remained volatile in the fourth quarter as legacy inventory phased out and new product approvals remain pending. Generics portfolio competitiveness remains a key focus area in the near term for both top line and gross margin. Nevertheless, led by vigabatrin franchise, Bora’s rare disease portfolio continued to gain impressive market share across dosage forms. The Company aims to actively refill pipelines in 2026 to regain profitable growth.
- The Group’s CDMO business delivered another strong quarter in both revenues and gross margin. Supported by expanded capacity and the addition of new dosage forms, CDMO revenues grew 53.8% year-over-year in 2025 to NT$10.64 billion, including internal orders. Excluding internal orders, revenues reached NT$7.50 billion, representing a 19.53% increase compared to 2024.
- As 2025 marked a year of post-merger integration and strategic consolidation, Bora achieved its highest operating cash flow margin in recent years at 34.74% in the fourth quarter, compared with -4.00% in the same period last year. This improvement reflects the transformation of the Bora Group into a more efficient organization operating on a larger and stronger platform. The Board has proposed a NT$10 cash dividend per share, demonstrating confidence in the Group’s strengthened cash generation and commitment to delivering sustainable returns to shareholders, reaching the highest yield rate proposed.
- Share capital increased 3.18% during the quarter from employee stock option exercise and convertible bond conversions.
Mr. Bobby Sheng, Chairman of Bora Group, stated, “2025 represented a pivotal year for Bora Group. Beyond post-acquisition integration, it was a year of disciplined capital allocation and balance sheet stewardship. Having stepped onto a larger growth platform, we deliberately reassessed optimal cash deployment, portfolio mix of both CDMO and Pharma Sales businesses and forthcoming return metrics under a stable equity structure. One year after closing the 2024 acquisitions, we achieved our highest operating cash flow margin, marking a complete turnaround from the same period last year when the Group first transitioned to its current scale.
The external environment was marked by significant shifts. We operated against a backdrop of renewed U.S. trade and industrial policy shifts, triggering supply chain realignment and foreign exchange fluctuations. At the same time, rapid AI adoption began reshaping manufacturing competitive dynamics, if not capital market funding flow. Concurrently, the Group faced competition in a handful core generic products that remain meaningful contributors to revenue and EBITDA. Discontinued operations aside, based on the reclassified financial statements for 2025 and 2024, EBITDA for continued operations declined 19.0% compared to 2024, but remains 12.5% higher than 2023, underscoring the structurally higher revenues and earnings base established over the past 2 years.
Despite these headwinds, the Group remained profitable and has preserved financial flexibility. Notably, we funded Bora’s largest CDMO CAPEX program in our history and executed the business transformation of Upsher-Smith entirely within existing credit facilities, without incremental equity dilution. While value expansion of this new Bora Group platform took longer than the Company expected, we believe the year demonstrates the resilience of our operating model, disciplined financial management, and our ability to execute strategic investments while maintaining earnings and balance sheet integrity.
We are especially delighted to share the contract renewal with GSK earlier this year. From day one, this partnership was built on mutual trust and a shared commitment to quality. With the latest developments, we are looking at a decade of collaboration with GSK and committing through 2030 speaks to our shared focus on value and reliability. We have also established new partnerships with several high-growth pharmaceuticals over the past few months, further expanding our client base across our North American network. These partners share our belief in an integrated and orchestrated supply chain model, leveraging our multi-site platform to support development, manufacturing, and commercialization needs.
To sum up, the CDMO rolling 12-month external order backlog, after a good quarter of digestion and less working days, arrived at US$264 million. Total external wins in 2025 reached a phenomenal US$482 million, of which 89% were commercial-stage orders and 16 molecules in pre-commercial stage, providing solid visibility into 2026 and beyond especially for Canada and Baltimore sites. At the same time, Bora continues to leverage a unified CDMO network to enhance cost competitiveness for our very own Upsher-Smith generics portfolio.
On the pharma sales side, Upsher-Smith today represents a structurally repositioned platform. Performance has been increasingly driven by lifecycle management, including continued maximization of the infantile spasm franchise, alongside active pipeline replenishment with a heightened focus on differentiated assets, particularly NCEs in rare diseases. Within Generics, we have confirmed 7 launches in 2026, including the recently approved Cyclosporine and an in-licensed product indicated for hyponatremia. We are also observing a more constructive environment for DLS than initially anticipated, with 2026 year-to-date market share maintained. Last but not least, based on our current knowledge of the relevant U.S. patent rulings, if TWi receives approval for Cladribine (gMavenclad), Upsher-Smith, as the exclusive distributor, would be positioned to launch the product in the U.S., subject to customary regulatory and commercial considerations.
Beyond our base expectation of launching more than 10 generic products annually, we have identified revenue and EBITDA accretive, bolt-on investment opportunities to further strengthen this business in 2026. These include progressively expanding our injectable and 505(b)(2) portfolios to enhance differentiation and economics, as well as deepening penetration across proprietary and specialty distribution channels. When we exit this year with a more diversified and better-calibrated product mix, we expect improved earnings resilience and more stable growth trajectory going forward.”
FY25 Operational Achievements & 2026 Outlook
Global CDMO Operations
Global CDMO operations revenue reached record highs for both the quarter and the full year, accounting for approximately 45.78% of reported revenues in the quarter and 39.43% for FY2025. In total, 2.5 billion doses were developed and manufactured. Revenue contribution from the top 20 global pharmaceutical companies declined slightly to 29% from the low-30% range previously, primarily reflecting the addition of several fast-growing pharmaceutical clients to the Company’s portfolio in recent years, with increasing contributions from their successful product launches.
As the Company continues to expand its CDMO capacity and capabilities, including approximately 10% additional aseptic fill/finish capacity and a net ~3% expansion in solid and liquid dosage capacity, Bora Group monitors utilization rate carefully across facilities. While the Company remains confident that investing in U.S. manufacturing capacity is strategically sound, given the importance of the U.S. pharmaceutical market and supply chain resilience, capital allocation must also align with prevailing industry investment cycles. Against this backdrop, a structural supply gap in single-use drug substance (DS) bioreactor capacity, projected to grow at an estimated 8–10% CAGR, reinforces the rationale for continued investment in Tanvex Biopharma (branded as Bora Biologics) as Bora Group expands its CDMO platform. Supported by a more favorable funding environment for early-stage biotech companies in the US, rapidly growing biologics pipeline, increasing FDA approvals, long product lifecycles, and Tanvex’s integrated access to Bora’ Group’s drug product (DP) fill/finish capabilities, the strategic platform presents a compelling long-term value creation opportunity. While this represents a near-term drag on reported earnings, the Company believes these investments are necessary to position Bora Group for long-term participation in the CDMO market that values quality and OTIF (On Time, In Full) delivery.
Pharma Sales Operations
Pharma Sales operations generated revenue of NT$2.64 billion in the fourth quarter, marking one of slowest quarters since the Upsher-Smith merger. For the full year, Pharma Sales declined 11.30% compared to 2024, excluding the impact of discontinued operations related to delisted products, and accounted for 60.48% of total revenues.
A key leading indicator in specialty pharma is the number of new patients, and across the Vigabatrin franchise, Upsher-Smith continues to demonstrate positive momentum on this front. Upsher-Smith intends to pursue enhanced customer segmentation to further increase salesforce effectiveness in 2026 with investments in key commercial functions and patient access to increase salesforce effectiveness.
Recent Investor Conference
Bora will host an English online earnings call at 9:30 p.m. Taiwan time on Mar. 12th, 2026, followed by an investor conference hosted by Taishin Securities at the Regent Taipei at 2:00 p.m. on Mar. 19th, 2026. Both events will cover the Company’s 2025 financial and business results and 2026 outlook.
English Online Earnings Presentation Link: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5255333/bora-pharmaceuticals-otcqx-boray-twse-6472
Bora will participate in 2026 Jefferies Asia Forum in March in Hong Kong and an East coast NDR in NYC and Boston. For 1:1 meetings with management, please contact your Jefferies and Sinopac representative.
Bora 2026 Earnings Schedule
Q1 2026: Expected in the 2nd week of May 2026
Q2 2026: Expected in the 2nd week of Aug 2026
Q3 2026: Expected in the 2nd week of Nov 2026
Q4 2026: Expected in the 2nd week of Mar 2027
Hashtag: #Bora
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.
For more, please visit:
https://www.bora-corp.com
https://www.boracdmo.com
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
Hashtag: #ZuelligPharma #EliLillyandCompany #Cialis #Healthcare #MensHealth #Healthcare #Pharmaceuticals
https://www.zuelligpharma.com/
https://www.linkedin.com/company/zuellig-pharma
The issuer is solely responsible for the content of this announcement.
About Zuellig Pharma
Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.
Media OutReach
Licensed Watch Dealer Times Avenue Marks Five Years amid Singapore’s Pre-Owned Watch Market Growth
As the global watch industry slows and fraud risks in the secondary channel draw public attention, Times Avenue is among Singapore’s secondhand luxury watch specialists seeing sustained growth on the back of shifting buyer preferences and tightening consumer scrutiny
SINGAPORE – Media OutReach Newswire – 3 August 2026 – Times Avenue by Horology Maison marks its five-year anniversary in 2026, as Singapore’s pre-owned luxury watch market expands amid a broader slowdown in the global watch industry.
A Growing Secondary Market and the Case for Regulated Dealers
The Bloomberg Subdial Watch Index, which tracks the 50 most-traded references by transaction value, recorded its best half-year performance since early 2022 in the first half of 2025, reflecting a broader shift in buyer preference towards the secondary channel.
The growth of the pre-owned segment has been driven by a combination of factors, including tighter supply of popular references at authorised dealers, record gold prices lifting new watch retail costs, and a shift among buyers towards immediate availability and market-reflective pricing.
Founded in 2020, Times Avenue has grown alongside this trend, transacting more than 3,000 authenticated timepieces from its Beach Road boutique over its first five years of operation. The boutique’s inventory is weighted towards luxury Swiss timepieces including Rolex, Patek Philippe, Audemars Piguet, Tudor and Cartier, with a focus on sought-after references that are typically subject to long waiting lists in the primary market.
At the same time, authentication and fraud risks in the secondary channel have drawn public attention, including the recent prosecution of an Italian national who attempted to trade a “fake” Rolex GMT Saru at a Singapore retailer. Both developments underline the importance of sourcing from licensed, regulated dealers.
Licensed secondhand goods dealers like Times Avenue operate under frameworks that impose customer due diligence, transaction reporting, record-keeping, and stock movement obligations. Exempted by the Singapore Police Force and a fully regulated dealer under the Ministry of Law, Times Avenue ensures that every watch sold undergoes rigorous in-house authentication before it reaches the client, and each piece is covered by an in-house warranty, giving buyers assurance of authenticity for every transaction.
Times Avenue also offers in-person buying from the public, trade-ins, consignment, and authentication, alongside retail, covering both the acquisition and resale ends of the secondary market.
Clients and prospective buyers can view current inventory, arrange private viewings, or request a sourcing consultation at https://horologymaison.com/contact-us/.
Hashtag: #TimesAvenue #PreOwnedWatches #LuxuryWatchesSingapore #WatchCollector #HorologyMaison
https://horologymaison.com/
https://www.facebook.com/timesavenuesg
https://www.instagram.com/timesavenuesg/
carousell: https://www.carousell.sg/u/timesavenuesg/
telegram: 
https://t.me/timesavenue
The issuer is solely responsible for the content of this announcement.
Times Avenue by Horology Maison
Times Avenue by Horology Maison is a Singapore-based luxury watch grey dealer established in 2021, offering authenticated new and pre-owned timepieces from Rolex, Patek Philippe, Audemars Piguet, Tudor, Cartier and other leading maisons. The company provides retail, buying, trade-in, consignment, sourcing and authentication services from its boutique at 371 Beach Road #02-55 City Gate, Singapore 199597. Times Avenue by Horology Maison is registered with the Ministry of Law as a Regulated Dealer (Registration No. PS20220002864) and holds SPF Exempted Second-Hand Goods Dealer status.
Over 200 industry leaders, trendsetters and cultural figures gather at The Orbit to celebrate the much-anticipated launch event
SHANGHAI, CHINA – Media OutReach Newswire – 3 August 2026 – De Beers Group unveiled the Desert diamonds campaign for Asia at West Bund Orbit in Shanghai. The immersive experience brought to life the authenticity, individuality and inner radiance embodied by Desert diamonds. Generating significant buzz across Shanghai, the event attracted distinguished guests, including government officials and ambassadors, retailers and industry partners, media and cultural influencers, artists and designers.
Designed by British architect Thomas Heatherwick, the West Bund Orbit’s fluid, ribbon‑like form resonates with Desert diamonds’ narrative of individuality, naturalness and fluidity, offering a visually perfect setting for the launch. The highlight of the evening was a sacred gong‑striking ceremony, symbolising the opening of a new era for Desert diamonds. Officiating at the gong-striking ceremony were Lynn Serfaty, General Manager, Natural Diamonds, De Beers Group; Annie Wong, Chief Operating Officer of Chow Tai Fook Jewellery Group; Winston Chow, Deputy General Manager of Chow Sang Sang Jewellery Group and Tommy Tse, Deputy CEO at Tse Sui Luen Jewellery Group. The ring the bell ceremony is accompanied by Loletta Lai, VP, Natural Diamond Marketing, APAC, De Beers Group and Sean Lin, VP, Sales, De Beers Group.
Government and diplomatic leaders joined the celebration to offer their congratulations. Taking the stage for a group photo were Mr. Sohail Shaikh, UK Deputy Trade Commissioner to China, UK Government / FCDO; Mr. Tom Simpson, MD, China, China-Britain Business Council; Ms. Phuti Joyce Tsipa, South African Consul-General in Shanghai; Ms. Bertha Amakali, Minister Counsellor of Namibia to China; Mr. Lin Qiang, President of Shanghai Diamond Exchange Center; Ms. Xu Yilei, Managing Director of the Natural Diamond Council Greater China; Ms. Meng Xiaojun, Chief Economist of NGTC; Shridaran Pillay, VP Government Affairs, De Beers Group, underscoring the event’s cross‑cultural significance.
“Desert diamonds captures the untamed beauty and power of the desert,” said Lynn Serfaty, “In China, natural diamonds are not imports—their origins are deeply rooted in ancient civilisation. The desert itself resonates with the Chinese cultural appreciation for transcendence, resilience, and the harmony between heaven and humanity.”
“Today’s consumers seek individual expression, true self, and self‑reward,” she continued, “Each Desert diamond is a response to this desire. Every Desert diamond presents a uniquely warm, natural colour and carries the imprint of billions of years. It is this cultural resonance that is driving the growing interest and appreciation of Desert diamonds in the Chinese market, representing the values most precious in our time: authenticity, individuality, and inner radiance.”
Departing from traditional jewellery launch formats, De Beers Group invited four “Real People” who embody the spirit of authenticity through their real‑life journeys to reveal the essence of Desert diamonds. The event opened with Desert diamonds “Real People” and sound healer Lear Tsui’s ethereal “Healing Trace” gong performance, guiding guests into a serene state of inner exploration. In the performance segment “Colour of Origin” that followed – Guo Yu’ang, a young Peking opera artist of the Mei School, honoured tradition with a graceful and elegant aria, conveying the beauty of heritage. The only female “Real People”, Shi Wei, China’s first F1 Academy female driver, made a stunning appearance wearing Desert diamonds jewellery at the “Blade of Resilience” segment. She shared with conviction: “True strength is often not outwardly expressed but built through intense focus. Just like the formation of natural diamonds—seemingly silent, yet enduring pressure over eons to achieve transformation.” Taking the stage at the finale “Ray of Refraction”, stand‑up comedian Liu Yang ignited the room with a series of humorous and heartfelt performances, and amidst the laughter, he led everyone into the moment of the very first reveal of Desert diamonds jewellery. Liu Yang shared: “True brilliance is not about being flawless, but about embracing every aspect of yourself, just as Desert diamonds reflects a unique individuality through the natural beauty of diamonds.”
At the heart of the celebration was a curated jewellery art exhibition, presenting Desert diamonds jewellery masterpieces by Chow Tai Fook, Chow Sang Sang and Tse Sui Luen, alongside De Beers Group’s iconic three‑stone collection and loose Desert diamonds. De Beers Group creatively partnered with bamboo weaving artist Xu Mingyu, who used the intangible cultural heritage of bamboo weaving to create immersive art installations throughout the venue. The Desert diamonds jewellery was placed amidst an intricate interplay of bamboo rhythms, sparking a poetic dialogue between contemporary jewellery design and millennia‑old craftsmanship. This distinctive Eastern aesthetic not only offered a fresh visual delight, but also interpreted the beauty of individuality, the authenticity of craftsmanship, and the radiance of time‑honoured tradition embodied by Desert diamonds from a local perspective, further underscoring De Beers Group’s Building Forever sustainability commitment.
To bring the experience to a memorable close, guests continued the journey through sensory party, where sound, scent and imagery combined to evoke the beauty at the heart of Desert diamonds. Interactive zones included a sand art experience allowing guests to co‑create with their fingertips, feeling the flow and eternity of the desert, a Gong Sound healing session using resonant frequencies to guide guests into a state of calm and introspection, and a Scents of the Desert fragrance experience blending warm amber and deep woody notes to outline the raw, pure beauty of the desert earth. Each experience acted as a different facet of a Desert diamond, collectively reflecting the themes of authenticity, individuality, and inner radiance.
To delve deeper into the spirit of the theme, De Beers Group hosted a series of panel talks, offering different perspectives on the evolving role of natural diamonds in modern life. Consumers were invited to participate in Natural Diamond Masterclasses, where they learned about the rarity, uniqueness and enduring value of natural diamonds, and gained further understanding of how to distinguish natural diamonds from laboratory‑grown diamonds. In addition, enamel painting workshops allowed guests to explore the dialogue between traditional craftsmanship and contemporary design.
Desert diamonds opens a new chapter in the celebration of natural diamonds, honouring their deep‑earth origin, inherent rarity, and cross‑cultural significance as symbols of individuality, natural beauty and self‑reward. Today, consumers increasingly look for pieces that reflect not only who they are, but how they choose to live, celebrate and express themselves. Desert diamonds answers that desire with a natural diamond expression shaped by individuality, authenticity and inner radiance. Looking ahead, De Beers Group will continue to celebrate the enduring wonder of natural diamonds and inspire a new generation to discover their relevance in today’s world. Desert diamonds breathe new life into “A Diamond is Forever”—because natural diamonds belong not only to eternity, but also to the here and now.
Please follow the official accounts to find more information regarding Desert diamonds.
| De Beers Group Official Website www.debeersgroup.com |
Natural Diamond Instagram Page： @ADiamondisForeverhk |
Hashtag: #Naturaldiamonds #Diamonds #DeBeersGroup #Desertdiamonds #ADiamondisForever
The issuer is solely responsible for the content of this announcement.
About De Beers Group
Established in 1888, De Beers Group is the world’s leading diamond company with expertise in the exploration, mining, marketing and retailing of diamonds. Together with its joint venture partners, De Beers Group employs more than 20,000 people across the diamond pipeline and is the world’s largest diamond producer by value, with diamond mining operations in Botswana, Canada, Namibia and South Africa. Innovation sits at the heart of De Beers Group’s strategy as it develops a portfolio of offers that span the diamond value chain, including its jewellery houses, De Beers London and Forevermark, and other pioneering solutions such as diamond sourcing and traceability initiatives Tracr and GemFair. De Beers Group also provides leading services and technology to the diamond industry in the form of education and laboratory services and a wide range of diamond sorting, detection and classification technology services. De Beers Group is committed to ‘
Building Forever,’ a holistic and integrated approach to sustainability that underpins our efforts to create meaningful impact for the people and places where our diamonds are discovered. Building Forever focuses on three key areas where, through collaborations and partnerships around the globe, we have an enhanced ability to drive positive impact; Livelihoods, Climate and Nature. De Beers Group is a member of the Anglo American plc group. For further information, visit www.debeersgroup.com.
